01—Abstract
Summary
Summary of the 10-Q filed October 30, 2025. Cited figures are marked; the original filing is the authoritative source.
DexCom, Inc. (DXCM) reported a strong third quarter for 2025, demonstrating significant year-over-year growth across key financial metrics.
Revenue increased by 22% to $1.21 billiona, driven by a robust expansion of their customer base and continued demand for their continuous glucose monitoring (CGM) systems. This top-line growth translated into substantial improvements in profitability, with gross profit up 23% and operating income soaring by 60%. Net income more than doubled, increasing by 111% to $283.8 million, indicating enhanced operational efficiency and effective cost management.
The company's financial position remains solid, with a significant increase in cash, cash equivalents, and short-term marketable securities to $3.32 billionb. This robust liquidity provides DexCom with ample resources to fund ongoing operations, capital expenditures, and strategic initiatives, including ongoing product development and potential expansion into new markets.
The successful launch of the Stelo biosensor and the FDA clearance for the Dexcom G7 15 Day CGM System further bolster the company's product portfolio and market reach. Despite ongoing legal proceedings and regulatory scrutiny, Dexcom has demonstrated impressive financial performance and a positive outlook for continued growth.
02—Key points
Key Highlights
- Revenue increased 22% year-over-year to $1.21 billion for the third quarter of 2025, driven by increased sales volume of disposable sensors and customer base expansion.
- Net income more than doubled, showing a 111% increase to $283.8 million for the third quarter, reflecting strong sales growth and operational efficiencies.
- Operating income surged by 60% to $242.5 million, highlighting improved profitability and cost management.
- The company ended the third quarter with a strong cash position of $3.32 billion in cash, cash equivalents, and short-term marketable securities.
- Significant investment in R&D continues, with a 16% increase in R&D expenses year-over-year, underscoring the commitment to innovation and future product development.
- The company experienced a substantial increase in accounts payable and accrued liabilities ($357.1 million increase), potentially indicating robust purchasing or accrual for ongoing operations and investments.
- DexCom received FDA clearance for the Dexcom G7 15 Day CGM System and launched its Stelo biosensor, expanding its product offerings and market reach.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q3 FY2025, Dexcom Inc kept $0.23.
- Revenue$1.21B100.0%
- Cost of revenue−$477.9M39.5%
- Gross profit$731.4M60.5%
- Operating costs−$488.9M40.4%
- Operating income$242.5M20.1%
- Interest, other & tax$41.3M3.4%
- Net income$283.8M23.5%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2025filed October 30, 2025Financial Statements
Q3 FY2025 against Q3 FY2024
| Line item | Q3 FY2025Q3 FY2024 | Change |
|---|---|---|
| Revenue | $1.21B$994.20M | +21.6% |
| Cost of Revenue | $477.90M$400.40M | +19.4% |
| Gross Profit | $731.40M$593.80M | +23.2% |
| R&D Expenses | $157.50M$135.40M | +16.3% |
| SG&A Expenses | $331.40M$306.40M | +8.2% |
| Operating Expenses | $488.90M$441.80M | +10.7% |
| Operating Income | $242.50M$152.00M | +59.5% |
| Interest Expense | $3.70M$3.70M | 0.0% |
| Net Income | $283.80M$134.60M | +110.8% |
| EPS (Basic) | $0.73$0.34 | +114.7% |
| EPS (Diluted) | $0.70$0.34 | +105.9% |
| Shares Outstanding (Basic) | 391.10M394.20M | −0.8% |
| Shares Outstanding (Diluted) | 407.40M410.20M | −0.7% |
05—Questions
Frequently Asked Questions
What is DexCom's revenue growth and profitability trend?
DexCom demonstrated strong revenue growth, with a 22% increase year-over-year to $1.21 billion for the third quarter of 2025. Profitability also saw significant improvements, with net income more than doubling (111% increase) to $283.8 million and operating income surging by 60% to $242.5 million, indicating effective cost management and operational efficiencies.
How is DexCom managing its cash and liquidity?
DexCom maintained a robust liquidity position, ending the third quarter with $3.32 billion in cash, cash equivalents, and short-term marketable securities. The company generated $1.15 billion in cash flow from operations for the first nine months of 2025, suggesting strong ongoing cash generation to fund operations, capital expenditures, and strategic initiatives.
What are the key product developments and market expansions for DexCom?
DexCom continues to innovate with product advancements and market expansions. Key developments include FDA clearance for the Dexcom G7 15 Day CGM System and the launch of its Stelo biosensor, targeting individuals with prediabetes and Type 2 diabetes who do not use insulin. These initiatives aim to broaden their customer base and address a wider range of metabolic health needs.
Are there any significant financial obligations or upcoming maturities DexCom needs to address?
DexCom has approximately $1.21 billion in 2025 Notes maturing on November 15, 2025, which the company intends to repay in cash. The company's ability to manage this near-term obligation is supported by its strong cash reserves and operational cash flow. Their debt-to-assets ratio of 0.33 as of September 30, 2025, indicates a healthy balance sheet for managing long-term obligations, including the 2028 Notes.
06—Continue